GeneDx (WGS) Competitors

$38.94 -0.55 (-1.39%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$38.54 -0.39 (-1.01%)

As of 04:10 AM Eastern

WGS vs. BLLN, OPCH, PRVA, CON, and LFST

Should you buy GeneDx stock or one of its competitors? MarketBeat compares GeneDx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GeneDx include Billiontoone (BLLN), Option Care Health (OPCH), Privia Health Group (PRVA), Concentra Group Holdings Parent (CON), and LifeStance Health Group (LFST). These companies are all part of the "healthcare" industry.

How does GeneDx compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and GeneDx (NASDAQ:WGS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Billiontoone has higher earnings, but lower revenue than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$354.54M	11.75	$7.45M	$0.55	164.71
GeneDx	$427.54M	2.70	-$21.02M	-$2.68	N/A

In the previous week, GeneDx had 12 more articles in the media than Billiontoone. MarketBeat recorded 22 mentions for GeneDx and 10 mentions for Billiontoone. Billiontoone's average media sentiment score of 0.55 beat GeneDx's score of 0.47 indicating that Billiontoone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	1 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.7% of GeneDx shares are owned by institutional investors. 29.6% of GeneDx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Billiontoone has a net margin of 0.00% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	N/A	N/A	N/A
GeneDx	-17.58%	9.15%	5.21%

Billiontoone currently has a consensus price target of $125.29, suggesting a potential upside of 38.30%. GeneDx has a consensus price target of $96.43, suggesting a potential upside of 147.63%. Given GeneDx's stronger consensus rating and higher probable upside, analysts clearly believe GeneDx is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

GeneDx beats Billiontoone on 8 of the 14 factors compared between the two stocks.

How does GeneDx compare to Option Care Health?

Option Care Health (NASDAQ:OPCH) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Option Care Health has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, GeneDx has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market.

Option Care Health has a net margin of 3.64% compared to GeneDx's net margin of -17.58%. Option Care Health's return on equity of 18.17% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Option Care Health	3.64%	18.17%	7.16%
GeneDx	-17.58%	9.15%	5.21%

Option Care Health currently has a consensus price target of $31.25, suggesting a potential upside of 57.99%. GeneDx has a consensus price target of $96.43, suggesting a potential upside of 147.63%. Given GeneDx's higher probable upside, analysts clearly believe GeneDx is more favorable than Option Care Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Option Care Health	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Option Care Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Option Care Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Option Care Health	$5.65B	0.55	$207.59M	$1.29	15.33
GeneDx	$427.54M	2.70	-$21.02M	-$2.68	N/A

98.1% of Option Care Health shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 1.7% of Option Care Health shares are owned by company insiders. Comparatively, 29.6% of GeneDx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, GeneDx had 2 more articles in the media than Option Care Health. MarketBeat recorded 22 mentions for GeneDx and 20 mentions for Option Care Health. Option Care Health's average media sentiment score of 0.77 beat GeneDx's score of 0.47 indicating that Option Care Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Option Care Health	11 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	1 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Option Care Health beats GeneDx on 12 of the 17 factors compared between the two stocks.

How does GeneDx compare to Privia Health Group?

GeneDx (NASDAQ:WGS) and Privia Health Group (NASDAQ:PRVA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

GeneDx has a beta of 2.06, meaning that its stock price is 106% more volatile than the broader market. Comparatively, Privia Health Group has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Privia Health Group has a net margin of 0.97% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat Privia Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Privia Health Group	0.97%	2.81%	1.61%

GeneDx presently has a consensus price target of $96.43, suggesting a potential upside of 147.63%. Privia Health Group has a consensus price target of $31.23, suggesting a potential upside of 38.01%. Given GeneDx's higher possible upside, analysts clearly believe GeneDx is more favorable than Privia Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Privia Health Group	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79

Privia Health Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Privia Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	2.70	-$21.02M	-$2.68	N/A
Privia Health Group	$2.12B	1.34	$22.92M	$0.16	141.44

61.7% of GeneDx shares are held by institutional investors. Comparatively, 94.5% of Privia Health Group shares are held by institutional investors. 29.6% of GeneDx shares are held by insiders. Comparatively, 5.7% of Privia Health Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, GeneDx and GeneDx both had 22 articles in the media. Privia Health Group's average media sentiment score of 0.54 beat GeneDx's score of 0.47 indicating that Privia Health Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	1 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Privia Health Group	7 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Privia Health Group beats GeneDx on 9 of the 15 factors compared between the two stocks.

How does GeneDx compare to Concentra Group Holdings Parent?

GeneDx (NASDAQ:WGS) and Concentra Group Holdings Parent (NYSE:CON) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

GeneDx has a beta of 2.06, indicating that its share price is 106% more volatile than the broader market. Comparatively, Concentra Group Holdings Parent has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

In the previous week, Concentra Group Holdings Parent had 2 more articles in the media than GeneDx. MarketBeat recorded 24 mentions for Concentra Group Holdings Parent and 22 mentions for GeneDx. Concentra Group Holdings Parent's average media sentiment score of 0.58 beat GeneDx's score of 0.47 indicating that Concentra Group Holdings Parent is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeneDx	1 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Concentra Group Holdings Parent	6 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.7% of GeneDx shares are owned by institutional investors. 29.6% of GeneDx shares are owned by company insiders. Comparatively, 8.1% of Concentra Group Holdings Parent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Concentra Group Holdings Parent has a net margin of 7.97% compared to GeneDx's net margin of -17.58%. Concentra Group Holdings Parent's return on equity of 47.14% beat GeneDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeneDx	-17.58%	9.15%	5.21%
Concentra Group Holdings Parent	7.97%	47.14%	6.48%

GeneDx presently has a consensus price target of $96.43, suggesting a potential upside of 147.63%. Concentra Group Holdings Parent has a consensus price target of $30.25, suggesting a potential upside of 17.09%. Given GeneDx's higher possible upside, equities analysts clearly believe GeneDx is more favorable than Concentra Group Holdings Parent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Concentra Group Holdings Parent	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Concentra Group Holdings Parent has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Concentra Group Holdings Parent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneDx	$427.54M	2.70	-$21.02M	-$2.68	N/A
Concentra Group Holdings Parent	$2.23B	1.48	$166.41M	$1.39	18.59

Summary

Concentra Group Holdings Parent beats GeneDx on 10 of the 16 factors compared between the two stocks.

How does GeneDx compare to LifeStance Health Group?

LifeStance Health Group (NASDAQ:LFST) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

LifeStance Health Group has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeStance Health Group	$1.42B	2.21	$9.66M	$0.06	135.00
GeneDx	$427.54M	2.70	-$21.02M	-$2.68	N/A

LifeStance Health Group has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, GeneDx has a beta of 2.06, indicating that its stock price is 106% more volatile than the broader market.

LifeStance Health Group presently has a consensus price target of $10.00, suggesting a potential upside of 23.46%. GeneDx has a consensus price target of $96.43, suggesting a potential upside of 147.63%. Given GeneDx's higher probable upside, analysts clearly believe GeneDx is more favorable than LifeStance Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeStance Health Group	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.11
GeneDx	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, LifeStance Health Group had 7 more articles in the media than GeneDx. MarketBeat recorded 29 mentions for LifeStance Health Group and 22 mentions for GeneDx. LifeStance Health Group's average media sentiment score of 0.64 beat GeneDx's score of 0.47 indicating that LifeStance Health Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeStance Health Group	9 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeneDx	1 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

85.5% of LifeStance Health Group shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 3.2% of LifeStance Health Group shares are owned by company insiders. Comparatively, 29.6% of GeneDx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

LifeStance Health Group has a net margin of 1.55% compared to GeneDx's net margin of -17.58%. GeneDx's return on equity of 9.15% beat LifeStance Health Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeStance Health Group	1.55%	1.56%	1.07%
GeneDx	-17.58%	9.15%	5.21%

Summary

LifeStance Health Group beats GeneDx on 10 of the 16 factors compared between the two stocks.

Get GeneDx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WGS vs. The Competition

Export

Metric	GeneDx	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.17B	$8.31B	$6.30B	$12.20B
Dividend Yield	N/A	2.92%	2.79%	5.30%
P/E Ratio	-14.53	22.95	21.00	25.58
Price / Sales	2.70	15.56	554.55	78.84
Price / Cash	17.23	83.95	42.94	55.34
Price / Book	4.55	5.62	9.75	6.66
Net Income	-$21.02M	$183.43M	$3.55B	$333.63M
7 Day Performance	-3.85%	0.28%	-0.53%	-0.11%
1 Month Performance	-41.77%	5.23%	1.20%	3.94%
1 Year Performance	-34.50%	4.94%	41.22%	36.07%

GeneDx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WGS GeneDx	3.7654 of 5 stars	$38.94 -1.4%	$96.43 +147.6%	-36.1%	$1.17B	$427.54M	N/A	1,300	Insider Trade Gap Down
BLLN Billiontoone	4.0232 of 5 stars	$81.40 +1.9%	$125.29 +53.9%	N/A	$3.67B	$305.11M	387.62	620	Analyst Forecast
OPCH Option Care Health	4.9353 of 5 stars	$20.45 -4.0%	$31.25 +52.8%	-37.3%	$3.34B	$5.65B	15.85	8,266	Analyst Downgrade
PRVA Privia Health Group	4.0405 of 5 stars	$23.99 -1.2%	$31.31 +30.5%	-6.9%	$3.05B	$2.12B	141.12	1,226	Earnings Report Insider Trade
CON Concentra Group Holdings Parent	3.8669 of 5 stars	$22.80 -0.1%	$30.00 +31.6%	+20.8%	$2.93B	$2.16B	17.54	13,133	Earnings Report Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WGS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGS) Competitors

WGS vs. BLLN, OPCH, PRVA, CON, and LFST

How does GeneDx compare to Billiontoone?

Summary

How does GeneDx compare to Option Care Health?

Summary

How does GeneDx compare to Privia Health Group?

Summary

How does GeneDx compare to Concentra Group Holdings Parent?

Summary

How does GeneDx compare to LifeStance Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WGS vs. The Competition

GeneDx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeneDx (WGS) Competitors

WGS vs. BLLN, OPCH, PRVA, CON, and LFST

How does GeneDx compare to Billiontoone?

Which has stronger earnings and valuation, BLLN or WGS?

Does the media refer more to BLLN or WGS?

Do insiders & institutionals have more ownership in BLLN or WGS?

Is BLLN or WGS more profitable?

Do analysts prefer BLLN or WGS?

Summary

How does GeneDx compare to Option Care Health?

Which has more risk & volatility, OPCH or WGS?

Is OPCH or WGS more profitable?

Do analysts prefer OPCH or WGS?

Which has stronger earnings and valuation, OPCH or WGS?

Do insiders & institutionals have more ownership in OPCH or WGS?

Does the media prefer OPCH or WGS?

Summary

How does GeneDx compare to Privia Health Group?

Which has more risk & volatility, WGS or PRVA?

Is WGS or PRVA more profitable?

Do analysts recommend WGS or PRVA?

Which has preferable earnings and valuation, WGS or PRVA?

Do institutionals & insiders have more ownership in WGS or PRVA?

Does the media favor WGS or PRVA?

Summary

How does GeneDx compare to Concentra Group Holdings Parent?

Which has more volatility and risk, WGS or CON?

Does the media favor WGS or CON?

Do insiders and institutionals have more ownership in WGS or CON?

Is WGS or CON more profitable?

Do analysts recommend WGS or CON?

Which has better valuation & earnings, WGS or CON?

Summary

How does GeneDx compare to LifeStance Health Group?

Which has stronger valuation and earnings, LFST or WGS?

Which has more risk and volatility, LFST or WGS?

Do analysts recommend LFST or WGS?

Does the media refer more to LFST or WGS?

Do institutionals and insiders have more ownership in LFST or WGS?

Is LFST or WGS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WGS vs. The Competition

GeneDx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools